dupilumab · Dupixent

Monoclonal antibody

Also known as REGN668

Approvedregulatory verdict

Evidence outlook

Approved: Asthma, Atopic Dermatitis, Chronic Obstructive Pulmonary Disease, Chronic Spontaneous Urticaria, Prurigo Nodularis, Eosinophilic Esophagitis

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Reliable signal

Also approved (7)
US
  • Allergic Fungal Rhinosinusitis: DUPIXENT for the treatment of adult and pediatric patients aged 6 years and older with allergic fungal rhinosinusitis (AFRS) who have a history of sino-nasal surgeryOutside this platform's coverageajmc.com
  • Treatment of adult and pediatric patients aged 6 years and older with allergic fungal rhinosinusitis (AFRS) who have a history of sino-nasal surgeryOutside this platform's coverageFDA label
  • Chronic rhinosinusitis with nasal polyps, eosinophilic oesophagitis, prurigo nodularis, chronic spontaneous urticaria, and bullous pemphigoidFDA label
Product first approved 2017
CN
  • Dupixent as an add-on maintenance treatment for adults with uncontrolled chronic obstructive pulmonary disease (COPD) characterized by raised blood eosinophils
Product first approved 2024sanofi.com
JP
  • Treatment of atopic dermatitis in patients who have not responded sufficiently to conventional treatments
Product first approved 2018PMDA
CA
  • Atopic Dermatitis DUPIXENT (dupilumab injection) is indicated for the treatment of patients aged 6 months and older with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. DUPIXENT can be used with or without topical corticosteroids. Asthma DUPIXENT is indicated as an add-on maintenance treatment in patients aged 6 years and older with severe asthma with a type 2/eosinophilic phenotype or oral corticosteroid-dependent asthma. DUPIXENT is not indicated for relief of acute bronchospasm...
Product first approved 2017Health Canada
EU
  • Atopic dermatitis Adults and adolescents Dupixent is indicated for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy. Children 6 months to 11 years of age Dupixent is indicated for the treatment of severe atopic dermatitis in children 6 months to 11 years old who are candidates for systemic therapy. Asthma Adults and adolescents Dupixent is indicated in adults and adolescents 12 years and older as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood...
Product first approved 2017EMA

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (46)
Asthma
NCT07309614 · Université de Sherbrooke
2026-01-29 – 2030-01 · Asthma Control
What this study did
NCT06191315 · Sanofi
2024-01-03 – 2028-12-21 · Wheezing, Asthma
What this study did
NCT06461949 · National Institute on Deafness and Other Communication Disorders (NIDCD)
2024-07-17 – 2024-07-17 · Allergic Fungal Rhinosinusitis (AFRS), Chronic Rhinosinusitis (CRS), Asthma, Nasal Polyps
What this study did
NCT03884842 · McMaster University
2019-07-01 – 2023-01-17 · Asthma
What this study did
NCT03620747 · Sanofi
2018-08-30 – 2022-02-18 · Asthma
What this study did
Atopic Dermatitis
NCT07919899 · Sanofi
2026-11-30 – 2028-07-25 · Dermatitis Atopic
What this study did
NCT06389136 · AbbVie
2024-06-14 – 2027-05 · Atopic Dermatitis
What this study did
NCT02612454 · Regeneron Pharmaceuticals
2015-10-15 – 2026-10-09 · Atopic Dermatitis
What this study did
NCT04678882 · Sanofi
2021-01-15 – 2023-10-28 · Atopic Dermatitis
What this study did
NCT03738397 · AbbVie
2019-02-21 – 2020-12-09 · Atopic Dermatitis
What this study did
NCT03912259 · Sanofi
2018-12-19 – 2020-02-14 · Atopic Dermatitis
What this study did
Chronic Obstructive Pulmonary Disease
Chronic Spontaneous Urticaria
Eosinophilic Esophagitis
NCT07112378 · Regeneron Pharmaceuticals
2025-11-10 – 2028-10-09 · Eosinophilic Esophagitis (EoE)
What this study did
Prurigo Nodularis
NCT06293053 · Sanofi
2024-05-15 – 2027-11-03 · Prurigo Nodularis
What this study did
Other / comorbidity
NCT04684524 · Sanofi
2020-12-01 – 2025-03-07 · Allergic Fungal Rhinosinusitis
What this study did
NCT05878093 · Sanofi
2023-05-16 – 2024-11-28 · Chronic Rhinosinusitis With Nasal Polyps
What this study did
NCT05545072 · Emory University
2023-10-26 – 2024-07-10 · Allergic Fungal Rhinosinusitis
What this study did
NCT02898454 · Sanofi
2016-11-28 – 2018-11-16 · Chronic Rhinosinusitis Phenotype With Nasal Polyps (CRSwNP)
What this study did
NCT02912468 · Sanofi
2016-12-05 – 2018-07-05 · Chronic Rhinosinusitis Phenotype With Nasal Polyps (CRSwNP)
What this study did
Phase 2/3 (4)
Atopic Dermatitis
Other / comorbidity
NCT05535738 · Wei-Che Ko
2022-11-15 – 2027-12-31 · Skin Inflammation, Allergic Contact Dermatitis
What this study did
NCT04206553 · Regeneron Pharmaceuticals
2020-10-28 – 2025-01-05 · Bullous Pemphigoid
What this study did
NCT04244006 · University Hospital, Toulouse
2020-07-23 – 2022-11-15 · Netherton Syndrome
What this study did
Phase 2 (51)
Asthma
NCT05720325 · The University of Texas Health Science Center at San Antonio
2023-03-29 – 2027-11-01 · Asthma, Allergic
What this study did
NCT05347771 · National Institute of Allergy and Infectious Diseases (NIAID)
2022-05-04 – 2027-03-15 · Asthma
What this study did
NCT05575037 · Brigham and Women's Hospital
2023-08-01 – 2026-12-30 · Nasal Polyps, Asthma, Aspirin-Induced, Aspirin-Exacerbated Respiratory Disease, Aspirin-Sensitive Asthma With Nasal Polyps
What this study did
NCT03387852 · Sanofi
2018-03-12 – 2019-08-07 · Asthma
What this study did
NCT02573233 · Sanofi
2016-01-27 – 2018-01-03 · Asthma
What this study did
NCT01312961 · Sanofi
2011-03 – 2012-10 · Asthma
What this study did
Atopic Dermatitis
NCT03359356 · Icahn School of Medicine at Mount Sinai
2018-01-09 – 2020-12-17 · Alopecia Areata
What this study did
NCT03736967 · Regeneron Pharmaceuticals
2018-11-12 – 2020-07-28 · Atopic Dermatitis
What this study did
NCT02407756 · Regeneron Pharmaceuticals
2015-03-31 – 2016-03-31 · Atopic Dermatitis
What this study did
NCT02210780 · Regeneron Pharmaceuticals
2014-08-05 – 2015-09-15 · Atopic Dermatitis
What this study did
NCT01979016 · Regeneron Pharmaceuticals
2013-12-31 – 2015-01-31 · Atopic Dermatitis (AD)
What this study did
NCT01859988 · Regeneron Pharmaceuticals
2013-05 – 2014-09 · Atopic Dermatitis
What this study did
NCT01548404 · Regeneron Pharmaceuticals
2012-04 – 2013-06 · Atopic Dermatitis
What this study did
Chronic Spontaneous Urticaria
NCT03749135 · Charite University, Berlin, Germany
2018-11-12 – 2021-07-07 · Chronic Spontaneous Urticaria, Recurrent Angioedema
What this study did
Eosinophilic Esophagitis
NCT06705387 · University of Colorado, Denver
2024-12-23 – 2027-03 · Eosinophilic Esophagitis
What this study did
NCT02379052 · Regeneron Pharmaceuticals
2015-05-12 – 2017-07-10 · Eosinophilic Esophagitis
What this study did
Other / comorbidity
NCT05866562 · Icahn School of Medicine at Mount Sinai
2024-07-11 – 2029-04-30 · Alopecia Areata
What this study did
NCT07908563 · Icahn School of Medicine at Mount Sinai
2026-08-27 – 2028-12 · Major Depressive Disorder
What this study did
NCT05551793 · Emma Guttman
2023-04-10 – 2028-10-31 · Alopecia Areata
What this study did
NCT07091175 · National University Hospital, Singapore
2025-11-27 – 2028-02-28 · Nephrotic Syndrome in Children, Nephrotic Syndrome Steroid-Dependent
What this study did
NCT06226610 · Akron Children's Hospital
2024-11-21 – 2027-12-31 · Pruritis
What this study did
NCT06477653 · National Institute of Allergy and Infectious Diseases (NIAID)
2025-02-05 – 2027-03-30 · Hypereosinophilic Syndrome
What this study did
NCT04600362 · Technical University of Munich
2021-03-30 – 2027-01-31 · Nummular Eczema
What this study did
NCT05831176 · Regeneron Pharmaceuticals
2023-05-03 – 2026-11-25 · Eosinophilic Gastritis (EoG), Eosinophilic Duodenitis (EoD), Eosinophilic Gastrointestinal Disease (EGID), Eosinophilic Gastroenteritis
What this study did
NCT05031455 · Scripps Clinic
2024-03-25 – 2026-04-20 · Aspirin-exacerbated Respiratory Disease
What this study did
NCT04362501 · Johns Hopkins University
2020-10-15 – 2025-09-30 · Chronic Sinusitis
What this study did
NCT04430179 · University of South Florida
2020-12-17 – 2025-07 · Severe Eosinophilic Chronic Sinusitis Without Nasal Polyposis
What this study did
NCT05128383 · Beth Israel Deaconess Medical Center
2023-01-13 – 2025-06-10 · Keloid
What this study did
NCT03679676 · Stanford University
2020-02-05 – 2025-05-02 · Hypersensitivity, Food Allergy, Hypersensitivity, Food, Peanut Hypersensitivity, Peanut Allergy
What this study did
NCT04148352 · Andrew J Long, PharmD
2021-10-18 – 2025-02-25 · Allergies Food Milk
What this study did
NCT04502966 · National Institute of Allergy and Infectious Diseases (NIAID)
2020-11-05 – 2025-02-20 · Allergic Rhinoconjunctivitis, Grass Pollen Allergy
What this study did
NCT04296864 · Andover Eye Associates
2020-02-10 – 2025-01 · Atopic Keratoconjunctivitis
What this study did
NCT03678545 · Children's Hospital Medical Center, Cincinnati
2021-05-15 – 2024-11-13 · Eosinophilic Gastritis, Eosinophilic Gastroenteritis
What this study did
NCT04256759 · Mayo Clinic
2020-09-01 – 2024-09-06 · Pruritus
What this study did
NCT05967884 · Ottawa Hospital Research Institute
2023-08-04 – 2024-08-01 · Breast Cancer
What this study did
NCT04442269 · Regeneron Pharmaceuticals
2020-09-15 – 2024-02-09 · Allergic Bronchopulmonary Aspergillosis
What this study did
NCT04678856 · Sanofi
2020-12-02 – 2024-01-29 · Chronic Rhinosinusitis Without Nasal Polyps, Sinusitis, Chronic Sinusitis, Sinus Disorder, Respiratory Disorder
What this study did
NCT03861455 · University Hospital, Toulouse
2019-07-15 – 2023-12-20 · Chronic Hand Eczema
What this study did
NCT04200755 · University of Cologne
2020-05-19 – 2023-11-30 · Localized Scleroderma
What this study did
NCT04920916 · University of Virginia
2021-05-25 – 2023-04-18 · COVID-19
What this study did
NCT03749148 · Charite University, Berlin, Germany
2018-12-10 – 2023-02-28 · Cholinergic Urticaria
What this study did
NCT04512339 · University Medical Center Groningen
2020-08-01 – 2022-08 · Hand Eczema
What this study did
NCT03682770 · Regeneron Pharmaceuticals
2018-10-03 – 2021-07-23 · Peanut Allergy
What this study did
NCT03793608 · Regeneron Pharmaceuticals
2019-03-12 – 2021-05-12 · Peanut Allergy
What this study did
NCT03886493 · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
2019-08-28 – 2020-10-06 · Prostate Cancer
What this study did
NCT03595488 · Rochester General Hospital
2018-09-05 – 2019-12-11 · Aspirin-exacerbated Respiratory Disease
What this study did
NCT03558997 · Regeneron Pharmaceuticals
2018-06-07 – 2019-06-13 · Allergic Rhinitis
What this study did
Phase 1/2 (3)
Other / comorbidity
NCT07277322 · Dan Feng
2026-09-01 – 2030-12-31 · Metastatic Colorectal Cancer, Liver Metastases
What this study did
Dupilumab_Metastatic NSCLCactive not recruiting
NCT05013450 · Thomas Marron
2021-09-10 – 2030-09-18 · Metastatic Non-small Cell Lung Cancer
What this study did
NCT06088771 · Icahn School of Medicine at Mount Sinai
2024-10-09 – 2027-07-01 · Non-Small Cell Lung Cancer
What this study did
Phase 1 (18)
Asthma
NCT03112577 · Regeneron Pharmaceuticals
2017-06-15 – 2019-12-09 · Asthma, Allergic
What this study did
Atopic Dermatitis
NCT05372003 · Mayo Clinic
2022-08-09 – 2024-02-23 · Atopic Dermatitis
What this study did
NCT03050151 · Regeneron Pharmaceuticals
2017-02-28 – 2018-02-12 · Atopic Disorders, Eczema, Atopic
What this study did
NCT02647086 · Regeneron Pharmaceuticals
2015-12 – 2016-07 · Atopic Dermatitis
What this study did
NCT01259323 · Regeneron Pharmaceuticals
2010-12 – 2012-07 · Dermatitis
What this study did
NCT01385657 · Regeneron Pharmaceuticals
2011-07-31 – 2012-03-31 · Atopic Dermatitis
What this study did
Eosinophilic Esophagitis
NCT07358234 · Mayo Clinic
2026-02-04 – 2027-12 · Eosinophilic Esophagitis (EoE)
What this study did
Other / comorbidity
NCT05649098 · Northwestern University
2023-06-12 – 2032-06-01 · Skin Diseases
What this study did
NCT06637306 · Rima Patel
2025-03-05 – 2027-03-10 · Locally Advanced Triple Negative Breast Cancer, TNBC - Triple-Negative Breast Cancer
What this study did
NCT03675022 · Brigham and Women's Hospital
2018-08-15 – 2022-07-01 · Sleep Apnea, Rhinosinusitis Chronic
What this study did
NCT05976386 · Sanofi
2021-06-08 – 2021-09-24 · Healthy Volunteers
What this study did
NCT05976373 · Sanofi
2015-01-05 – 2015-03-30 · Healthy Volunteers
What this study did
NCT05976360 · Sanofi
2014-11-02 – 2015-01-17 · Healthy Volunteer
What this study did
NCT01537653 · Sanofi
2012-03 – 2012-10 · Healthy
What this study did
NCT01537640 · Sanofi
2012-02 – 2012-07 · Healthy
What this study did
NCT01484600 · Regeneron Pharmaceuticals
2011-12 – 2012-02 · Healthy
What this study did
NCT01015027 · Regeneron Pharmaceuticals
2009-10 – 2010-07 · Healthy
What this study did
Phase 4 (57)
Asthma
NCT06818019 · University Hospital, Toulouse
2025-12-15 – 2029-12-31 · Severe Asthma
What this study did
NCT04743791 · Sally E. Wenzel MD
2022-10-17 – 2028-06 · Asthma
What this study did
NCT06385236 · University of California, San Diego
2024-02-19 – 2028-01-31 · Moderate to Severe Asthma
What this study did
NCT03694158 · Boston Children's Hospital
2021-09-08 – 2027-03 · Asthma
What this study did
NCT04380038 · University of Virginia
2022-05-01 – 2026-12-31 · Asthma
What this study did
NCT05942222 · Copenhagen University Hospital, Rigshospitalet
2023-04-27 – 2026-05-01 · Chronic Rhinosinusitis With Nasal Polyps, Asthma; Eosinophilic, Eosinophilia
What this study did
NCT06556264 · Dr. Andrew Thamboo, MD
2024-08 – 2025-12 · Chronic Rhinosinusitis With Nasal Polyps, Asthma
What this study did
NCT04998604 · Sanofi
2021-09-27 – 2024-12-27 · Chronic Rhinosinusitis With Nasal Polyps, Asthma
What this study did
NCT04203797 · Regeneron Pharmaceuticals
2020-07-16 – 2023-07-15 · Asthma
What this study did
NCT05036733 · University of Michigan
2022-02-22 – 2023-06-29 · Asthma
What this study did
Atopic Dermatitis
NCT07905547 · Sanofi
2026-10-28 – 2028-08-02 · Atopic Dermatitis
What this study did
NCT05858619 · University of California, San Francisco
2023-02-01 – 2028-02-01 · Atopic Dermatitis
What this study did
NCT07187089 · Regeneron Pharmaceuticals
2025-11-11 – 2028-01-05 · Severe Atopic Dermatitis (AD)
What this study did
NCT05268107 · University of Michigan
2023-01-25 – 2028-01 · Atopic Dermatitis
What this study did
NCT05042258 · Northwestern University
2024-08-12 – 2027-06 · Atopic Dermatitis, Sleep Disturbance
What this study did
NCT05983068 · Sanofi
2024-02-22 – 2027-05-19 · Dermatitis Atopic
What this study did
NCT06004986 · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
2023-08-14 – 2026-12-31 · Atopic Dermatitis, Atopic Dermatitis Eczema
What this study did
NCT05642208 · Nantes University Hospital
2023-03-08 – 2026-08-27 · Atopic Dermatitis, Eczema, Atopic
What this study did
NCT06116526 · Johns Hopkins University
2024-04-01 – 2026-07-18 · Atopic Dermatitis
What this study did
NCT05436535 · National Institute of Allergy and Infectious Diseases (NIAID)
2022-11-21 – 2025-10-24 · Atopic Dermatitis
What this study did
NCT05285839 · Psoriasis Treatment Center of Central New Jersey
2022-04-19 – 2024-12-15 · Atopic Dermatitis
What this study did
NCT05590585 · Regeneron Pharmaceuticals
2023-01-11 – 2024-11-14 · Moderate-to-Severe Atopic Dermatitis, Atopic Eczema
What this study did
NCT05680298 · Sanofi
2023-02-22 – 2024-03-15 · Atopic Dermatitis
What this study did
NCT05265234 · OptiSkin Medical
2022-03-01 – 2024-03-01 · Eczema, Atopic Dermatitis
What this study did
NCT05624112 · Sanofi
2022-11-25 – 2024-01-25 · Atopic Dermatitis, Dermatitis Atopic
What this study did
NCT04895423 · National Medical Research Center for Children's Health, Russian Federation
2021-11-25 – 2023-07-25 · Atopic Dermatitis
What this study did
NCT03293030 · University of California, San Francisco
2018-10-22 – 2023-02-23 · Atopic Dermatitis, Atopic Dermatitis Eczema, Eczema, Atopic Dermatitis and Related Conditions
What this study did
NCT03667014 · University of California, San Francisco
2018-11-01 – 2022-12-15 · Atopic Dermatitis, Atopic Dermatitis Eczema
What this study did
NCT04718870 · Sanofi
2021-02-19 – 2022-11-30 · Dermatitis Atopic
What this study did
NCT04358224 · Jonathan A. Bernstein, MD
2020-09-01 – 2022-11-18 · Atopic Dermatitis, Eczema
What this study did
NCT04823130 · Sanofi
2021-04-22 – 2022-08-30 · Dermatitis Atopic
What this study did
NCT04033367 · Sanofi
2019-08-22 – 2021-10-06 · Atopic Dermatitis
What this study did
NCT04447417 · Sanofi
2020-07-16 – 2021-06-17 · Atopic Dermatitis
What this study did
NCT04520308 · Eric Simpson
2020-09-01 – 2021-03-31 · Atopic Dermatitis, AD, Eczema
What this study did
NCT03389893 · National Institute of Allergy and Infectious Diseases (NIAID)
2018-07-25 – 2020-09-09 · Atopic Dermatitis (AD)
What this study did
Chronic Obstructive Pulmonary Disease
NCT07053423 · Sanofi
2025-09-22 – 2029-02-02 · Chronic Obstructive Pulmonary Disease
What this study did
Eosinophilic Esophagitis
NCT06352073 · University of North Carolina, Chapel Hill
2024-05-16 – 2026-12 · Eosinophilic Esophagitis, EoE
What this study did
NCT06665971 · University of California, San Diego
2024-11-10 – 2026-11-14 · Eosinophilic Esophagitis (EoE)
What this study did
NCT05247866 · Children's Hospital of Philadelphia
2022-06-16 – 2025-01-21 · Eosinophilic Esophagitis
What this study did
Other / comorbidity
NCT06188871 · University of Rochester
2024-06-01 – 2027-06-01 · Chronic Rhinosinusitis With Nasal Polyps
What this study did
NCT03935971 · Brigham and Women's Hospital
2019-12-18 – 2027-03-31 · Allergic Contact Dermatitis
What this study did
NCT05094570 · University of Virginia
2022-09-01 – 2026-12-31 · Nasal Polyps, Staphylococcus Aureus
What this study did
NCT04869436 · London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
2021-07-19 – 2026-09-16 · Chronic Rhinosinusitis With Nasal Polyps, Olfactory Disorder
What this study did
NCT06750471 · Madigan Army Medical Center
2021-10-14 – 2025-12 · Nasal Polyps, Sinusitis, Chronic Disease
What this study did
Early phase / not applicable (6)
Atopic Dermatitis
NCT04878770 · Erasmus Medical Center
2021-08-16 – 2025-01-01 · Dermatitis, Atopic
What this study did
NCT06509243 · Medical University of Silesia
2023-02-10 – 2024-04-10 · Atopic Dermatitis
What this study did
NCT03983460 · Association pour la Recherche Clinique et Immunologique
2020-03-09 – 2021-09 · Atopic Dermatitis
What this study did
NCT04066998 · Centre Hospitalier Universitaire de Besancon
2019-12 – 2021-08 · Conjunctival Diseases, Atopic Dermatitis, Side Effect
What this study did
Other / comorbidity
NCT06501807 · University Hospital, Lille
2024-07-11 – 2035-01-02 · Rhinosinusitis Chronic, Nasal Polyps
What this study did
NCT06743581 · Centre hospitalier de l'Université de Montréal (CHUM)
2025-08-19 – 2030-02 · Non-Small Cell Lung Cancer, Immunotherapy, Neoadjuvant Therapy
What this study did
Used as active comparator (22)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 3 (8)
Atopic Dermatitis
NCT07783425 · Pfizer
2026-08-24 – 2029-06-15 · Atopic Dermatitis
What this study did
NCT07754786 · Innovent Biologics (Suzhou) Co. Ltd.
2026-09-15 – 2028-08-26 · Atopic Dermatitis
What this study did
NCT06884891 · Qilu Pharmaceutical Co., Ltd.
2025-04 – 2028-04 · Atopic Dermatitis
What this study did
NCT07386743 · Jiangsu Genscend Biopharmaceutical Co., Ltd
2026-01-29 – 2028-01 · Atopic Dermatitis (AD)
What this study did
NCT04345367 · Pfizer
2020-06-11 – 2021-07-13 · Atopic Dermatitis
What this study did
NCT03720470 · Pfizer
2018-10-29 – 2020-03-06 · Dermatitis, Dermatitis, Atopic, Eczema, Skin Diseases, Skin Diseases, Genetic, Genetic Diseases, Inborn, Skin Diseases, Eczematous, Hypersensitivity, Hypersensitivity, Immediate, Immune System Diseases
What this study did
Chronic Spontaneous Urticaria
NCT06868212 · Novartis Pharmaceuticals
2025-07-11 – 2027-05-17 · Chronic Spontaneous Urticaria (CSU)
What this study did
Phase 2 (5)
Atopic Dermatitis
NCT07399067 · Innovent Biologics (Suzhou) Co. Ltd.
2026-02-06 – 2027-05-27 · Atopic Dermatitis
What this study did
NCT07330934 · Innovent Biologics (Suzhou) Co. Ltd.
2025-12-31 – 2026-08-18 · Atopic Dermatitis
What this study did
NCT06881251 · Janssen Research & Development, LLC
2025-02-26 – 2026-04-07 · Dermatitis, Atopic
What this study did
NCT05470114 · LEO Pharma
2022-05-19 – 2023-10-09 · Atopic Dermatitis
What this study did
NCT04791319 · Janssen Research & Development, LLC
2021-05-03 – 2022-03-31 · Dermatitis, Atopic
What this study did
Phase 1 (8)
Atopic Dermatitis
NCT07027527 · Apogee Therapeutics, Inc.
2025-06-04 – 2027-12 · Atopic Dermatitis
What this study did
NCT07358156 · Chong Kun Dang Pharmaceutical
2026-02-09 – 2026-11-16 · Atopic Dermatitis
What this study did
NCT07411755 · Jiangsu Genscend Biopharmaceutical Co., Ltd
2026-03-05 – 2026-08-24 · Atopic Dermatitis (AD)
What this study did
NCT06193434 · Innovent Biologics (Suzhou) Co. Ltd.
2024-01-05 – 2025-08-20 · Healthy Participants, Atopic Dermatitis Patients
What this study did
NCT06614907 · Qilu Pharmaceutical Co., Ltd.
2024-08-31 – 2024-12-27 · Atopic Dermatitis
What this study did
Other / comorbidity
NCT07791342 · Mabwell (Shanghai) Bioscience Co., Ltd.
2026-04-22 – 2026-08-17 · Healthy Participants
What this study did
NCT07334496 · Gan & Lee Pharmaceuticals.
2026-03-09 – 2026-07-17 · Biosimilarity
What this study did
NCT07502534 · Innovent Biologics (Suzhou) Co. Ltd.
2026-04-24 – 2026-07-07 · Healthy Volunteers
What this study did
Phase 4 (1)
Other / comorbidity
NCT07268313 · Copenhagen University Hospital, Rigshospitalet
2025-04-03 – 2027-06-01 · Nasal Polyps
What this study did
Studied as part of a combination product (1)

Studies of a fixed-dose combination that contains this drug. The combination is the product under test, so these are that product's evidence rather than this one's; the link is kept because the drug really was administered.

Phase 4 (1)
Atopic Dermatitis
NCT07352566 · University of California, San Francisco
2026-08-01 – 2030-06-01 · Psoriasis, Atopic Dermatitis
What this study did
Appears in other studies (2)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Phase 1 (1)
Other / comorbidity
NCT06369467 · Regeneron Pharmaceuticals
2024-05-17 – 2027-08-31 · Food Allergy
What this study did
Phase 4 (1)
Atopic Dermatitis
NCT06465732 · Second Affiliated Hospital, Zhejiang University, School of Medicine
2025-01 – 2026-07 · Atopic Dermatitis
What this study did

Competitive landscape

This mechanism is crowded: 10 other tracked programmes target it, none of them ahead of this one.

This drug's own stage for Asthma: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Dupilumab (Dupixent): this drugApprovedMonoclonal antibodyIL-4R-alphaPartial signal
NCT03782532: Change in pre-bronchodilator FEV1, baseline to Week 12: LS mean difference 0.31 L favoring dupilumab vs placebo (95% CI 0.23-0.39); p<0.0001 (primary analysis population, n=414).
Albuterol (Armstrong Albuterol HFA)ApprovedSmall moleculeBeta-2 adrenergic receptorPartial signalNo reviewed efficacy summary in this indication
Albuterol (Ventolin)ApprovedSmall moleculeBeta-2 adrenergic receptorWeak signalNo reviewed efficacy summary in this indication
Albuterol / Budesonide (Airsupra)ApprovedCombinationBeta-2 adrenergic receptor, Glucocorticoid receptorReliable signal
NCT05505734: Time to First Severe Asthma Exacerbation, While on Treatment Strategy, Interim Analysis Data Cut-off (Participants Aged >=12 Years) (From treatment initiation until the earliest occurrence of study completion, treatment discontinuation, step-up in maintenance therapy, or interim analysis DCO, up to one year following treatment initiation.): BDA MDI (PT027) 160/180 μg 62/1209 vs AS MDI (PT007) 180 µg 110/1212
NCT03769090: Number of Participants With a Severe Asthma Exacerbation Event (From randomization up to a discontinuation of randomized treatment or a change in maintenance therapy. The mean and median reporting period for all participants was 44 and 48 weeks, respectively.): BDA MDI 160/180 μg (Full Analysis Set; >=12 Years) 207/1013 | BDA MDI 80/180 μg (Full Analysis Set) 241/1054 vs AS MDI 180 μg (Full Analysis Set; >=12 Years) 266/1014 | AS MDI 180 μg (Full Analysis Set) 276/1056
Albuterol Sulfate (Amphastar)ApprovedSmall moleculeBeta-2 adrenergic receptornot yet gradedNo reviewed efficacy summary in this indication
Albuterol Sulfate (Proventil HFA)ApprovedSmall moleculeBeta-2 adrenergic receptornot yet gradedNo reviewed efficacy summary in this indication
AminophyllineApprovedSmall moleculePhosphodiesterase (multi-subtype)not yet gradedNo reviewed efficacy summary in this indication
Beclomethasone (QVAR)ApprovedSmall moleculeGlucocorticoid receptorReliable signal
NCT02040766: Baseline-adjusted trough morning percent predicted FEV1, AUEC(0-12 wk) vs placebo: BDP 80 ug/day BAI +2.81 (95% CI 0.80 to 4.82), p=0.0063; BDP 160 ug/day BAI +0.63, p=0.5332; BDP 80 ug/day MDI +0.92, p=0.3649; BDP 160 ug/day MDI +1.09, p=0.2823 (CT.gov posted results).
Beclomethasone Dipropionate / Formoterol Fumarate / Glycopyrrolate (Trimbow)
ApprovedUS marketing discontinued
Small moleculeGlucocorticoid receptor / Beta-2 adrenergic receptor / Muscarinic M3 receptor (ICS/LABA/LAMA triple combination)Reliable signalNo reviewed efficacy summary in this indication
Benralizumab (Fasenra)ApprovedMonoclonal antibodyIL-5 receptor alpha, IL-5 receptor alpha (IL-5Rα / CD125); Fc region additionally engages FcγRIIIa on NK cells (ADCC), IL-5 receptor alpha (IL5RA) on eosinophils/basophilsReliable signal
NCT03170271: Annualized Rate of Asthma Exacerbations Over the Treatment Period (up to Week 24) (Baseline (Week 0) up to Week 24): Benralizumab 0.94 Events/year (95% CI 0.79 to 1.12) | Placebo 1.86 Events/year (95% CI 1.54 to 2.24)
NCT01928771: Annual asthma exacerbation rate: 0.73 events/year with benralizumab 30 mg q4w vs 1.33 with placebo (rate ratio 0.55, 95% CI 0.42-0.71; p<0.001); 0.65 events/year with benralizumab 30 mg q8w vs 1.33 with placebo (rate ratio 0.49, 95% CI 0.37-0.64; p<0.001).
Budesonide (Pulmicort)ApprovedSmall moleculeGlucocorticoid receptor agonistnot yet gradedNo reviewed efficacy summary in this indication
Budesonide (Pulmicort Flexhaler)ApprovedSmall moleculeGlucocorticoid receptor agonistnot yet gradedNo reviewed efficacy summary in this indication
Budesonide / Formoterol Fumarate (SYMBICORT)ApprovedCombinationGlucocorticoid receptor; Beta-2 adrenergic receptorPartial signal
NCT00646321: Evening PEF (primary) better with once- or twice-daily budesonide/formoterol than budesonide alone (P<or=.027).
Budesonide / Glycopyrrolate / Formoterol Fumarate (Breztri Aerosphere)ApprovedSmall moleculeGlucocorticoid receptor; Muscarinic M3; Beta-2 adrenergicPartial signal
NCT04609878: Change From Baseline in FEV1 AUC0-3 (L) at Week 24 (Week 24): BGF MDI 320/14.4/9.6 μg BID 0.281 Liters (Standard Error 0.018) | BGF MDI 320/28.8/9.6 μg BID 0.316 Liters (Standard Error 0.014) vs BFF MDI 320/9.6 μg BID 0.249 Liters (Standard Error 0.014) | Symbicort® pMDI 320/9 μg BID 0.22 Liters (Standard Error 0.014)
NCT04609904: Change From Baseline in FEV1 AUC0-3 (L) at Week 24 (Week 24): BGF MDI 320/14.4/9.6 μg BID 0.374 Liters (Standard Error 0.019) | BGF MDI 320/28.8/9.6 μg BID 0.354 Liters (Standard Error 0.015) vs BFF MDI 320/9.6 μg BID 0.219 Liters (Standard Error 0.015) | Symbicort® 320/9 μg BID 0.239 Liters (Standard Error 0.015)
Ciclesonide (Alvesco)ApprovedSmall moleculeGlucocorticoid receptorReliable signal
NCT00174720: FEV1 change from baseline, source's own labeled primary endpoint (average of weeks 12 and 16): ciclesonide 80mcg b.i.d. +0.30L (p<0.0001), 160mcg q.d. +0.19L (p<0.0001), 80 b.i.d./160 q.d. stepped +0.19L (p<0.0001), vs placebo +0.06L (p=0.0251); at week 16 alone, all ciclesonide arms significant vs placebo (p<=0.015), magnitude not given for week 16 alone
NCT00163397: Change in FEV1: non-inferiority of ciclesonide to budesonide demonstrated (one-sided p = 0.0021), confirmed in the ITT analysis
DepemokimabApprovedMonoclonal antibodyIL-5Partial signal
NCT04719832: Annualized Rate of Clinically Significant Exacerbations up to 52 Weeks (Up to Week 52): Placebo 1.11 Exacerbation per participant per year (95% CI 0.86 to 1.43) | GSK3511294 0.46 Exacerbation per participant per year (95% CI 0.36 to 0.58)
Fluticasone Furoate (Arnuity Ellipta)ApprovedSmall moleculeGlucocorticoid receptorPartial signal
NCT00603278: Mean Change From Baseline in Trough (Evening Pre-dose and Pre- Rescue Bronchodilator) FEV1 at Week 8 (Baseline and Week 8): GW685698X 100 µg OD 0.142 Liters (Standard Error 0.0403) | GW685698X 200 µg OD 0.173 Liters (Standard Error 0.0404) | GW685698X 300 µg OD 0.228 Liters (Standard Error 0.0402) | GW685698X 400 µg OD 0.215 Liters (Standard Error 0.0414) vs Placebo -0.065 Liters (Standard Error 0.0395) | FP 250 µg BID 0.16 Liters (Standard Error 0.0409)
NCT00603382: Mean Change From Baseline in Trough (Evening Pre-dose and Pre- Rescue Bronchodilator) FEV1 at Week 8 (Baseline and Week 8): GW685698X 25 µg OD 0.239 Liters (Standard Error 0.0428) | GW685698X 50 µg OD 0.266 Liters (Standard Error 0.042) | GW685698X 100 µg OD 0.341 Liters (Standard Error 0.0396) | GW685698X 200 µg OD 0.367 Liters (Standard Error 0.0428) vs Placebo 0.137 Liters (Standard Error 0.0428) | FP 100 µg BID 0.243 Liters (Standard Error 0.0411)
Fluticasone Furoate / Umeclidinium / Vilanterol (Trelegy Ellipta)ApprovedSmall moleculeMuscarinic acetylcholine receptor (M3), Beta-2 adrenergic receptor, Glucocorticoid receptor, Glucocorticoid receptor / Beta-2 adrenergic receptor / Muscarinic M3 receptor (ICS/LABA/LAMA triple combination)Reliable signal
NCT02924688: Week 24 trough FEV1: FF/UMEC/VI vs FF/VI treatment differences 0.096 L (95% CI 0.052 to 0.139; p<0.001), 0.110 L (95% CI 0.066 to 0.153; p<0.001), 0.082 L (95% CI 0.039 to 0.125; p<0.001), and 0.092 L (95% CI 0.049 to 0.135; p<0.001).
NCT04937387: Change From Baseline in Trough Forced Expiratory Volume in 1 Second (FEV1) at Week 12 (100ug FF) (Baseline (pre-dose at Day 1) and Week 12): Fluticasone Furoate [FF] 100 ug/ Umeclidinium [UMEC] 62.5 ug/ Vilanterol [VI] 25 ug 0.136 Liters (Standard Error 0.0316) vs Fluticasone Furoate [FF] 100 Microgram[ug] / Vilanterol [VI] 25 ug 0.078 Liters (Standard Error 0.0321)
Fluticasone Furoate / Vilanterol (Breo Ellipta)ApprovedSmall moleculeBeta-2 adrenergic receptor, Glucocorticoid receptor, Glucocorticoid receptor / Beta-2 adrenergic receptorReliable signal
NCT01086384: Number of Participants With 1 or More Severe Asthma Exacerbations (Baseline to Follow-up (up to 76 weeks of treatment)): FF/VI 100/25 µg 154/1009 vs FF 100 µg 186/1010
NCT03248128: Absolute Weighted Mean of Forced Expiratory Volume in 1 Second (FEV1) (0-4 Hours) at Week 12 in 5-17 Year Old Population (Week 12): Participants Who Received FF/ VI FDC 2.082 Liters (Standard Deviation 0.7598) vs Participants Who Received FF 1.994 Liters (Standard Deviation 0.6998)
Fluticasone PropionateApprovedSmall moleculeGlucocorticoid receptornot yet gradedNo reviewed efficacy summary in this indication
Fluticasone Propionate / Salmeterol (Advair Diskus)ApprovedSmall moleculeGlucocorticoid receptor / Beta-2 adrenergic receptorPartial signal
NCT00920959: Change in percent predicted PM PEF: FSC 100/50 QD did not give significantly greater improvement than FP 100 QD (superiority not shown) missed
Fluticasone Propionate / Salmeterol (Advair HFA)ApprovedCombinationGlucocorticoid receptor / Beta-2 adrenergic receptor, Beta-2 adrenergic receptor, Glucocorticoid receptorPartial signal
NCT00448435: Adjusted Mean Change From Baseline in Morning PEF (Peak Expiratory Flow) During the 4-week Treatment Periods (Crossover Period Weeks 1-4, and 7-10): SFC 50/100 Mcg/Day 14.3 Liters/minute (Standard Error 4.53) vs SLM 50 Mcg + FP 100 Mcg/Day 17.1 Liters/minute (Standard Error 4.53)
Levalbuterol (Xopenex HFA)Approved—beta-2 adrenergic receptornot yet gradedNo reviewed efficacy summary in this indication
Mepolizumab (Nucala)ApprovedMonoclonal antibodyIL-5, Interleukin-5 (IL-5), ligand-neutralizingWeak signal
NCT01691508: Number of Participants With the Indicated Percent Reduction From Baseline in Oral Corticosteroid (OCS) Dose During Weeks 20 to 24 While Maintaining Asthma Control (Baseline; Weeks 20 to 24): Mepolizumab 100 mg SC — 90 to 100%: 16/69; 75 to <90%: 12/69; 50 to <75%: 9/69; >0 to <50%: 7/69; No decrease /lack of asthma control/early WD: 25/69 vs Placebo — 90 to 100%: 7/66; 75 to <90%: 5/66; 50 to <75%: 10/66; >0 to <50%: 7/66; No decrease /lack of asthma control/early WD: 37/66
NCT01000506: Number of Clinically Significant Exacerbations of Asthma Per Year (From randomization (Week 0) to Week 52 or early withdrawal (EW)): Mepolizumab 75 mg IV 1.24 Exacerbations per year | Mepolizumab 250 mg IV 1.46 Exacerbations per year | Mepolizumab 750 mg IV 1.15 Exacerbations per year vs Placebo IV 2.4 Exacerbations per year
MethylprednisoloneApprovedSmall moleculeGlucocorticoid receptor agonistnot yet gradedNo reviewed efficacy summary in this indication
Mometasone Furoate / Formoterol Fumarate (Dulera / Zenhale)ApprovedSmall moleculeGlucocorticoid receptor; Beta-2 adrenergic receptorPartial signal
NCT00383240: Primary endpoint (FEV1 AUC(0-12h) change from baseline to week 12, L*h), MF/F 200/10 mcg vs MF 200 mcg alone: 3.19 (SD 3.98) vs 1.31 (SD 3.98); p<.001.
NCT00383552: AUC(0-12h) change from baseline to Week 12 in FEV1: MF/F 100/10 mcg BID +4.00 L*h (SD 3.71) vs MF 100 mcg BID +2.53 L*h (SD 3.71); ANCOVA p=0.001.
Montelukast (Singulair)ApprovedSmall moleculeCysteinyl leukotriene receptor 1 (CysLT1)Weak signal
NCT00489346: Primary endpoint (percentage of asthma rescue-free days over 12 months): montelukast 5mg QD (n=495) was non-inferior to fluticasone 100mcg BID (n=499) — 495+499=994, exactly matching this record's enrollment. LS mean difference -2.8% (95% CI -4.7% to -0.9%), within the pre-specified -7% noninferiority margin.
Omalizumab (Xolair)ApprovedMonoclonal antibodyIgE (immunoglobulin E), IgEWeak signalNo reviewed efficacy summary in this indication
Primatene MistApprovedSmall moleculeAdrenergic receptor (non-selective, alpha+beta), Alpha-1 and beta-1/beta-2 adrenergic receptors, Adrenergic receptors, nonselectivePartial signal
NCT01460511: Primary endpoint, AUC0-6h of percent change in FEV1 at week 4: numerical benefit of epinephrine HFA over placebo, not statistically significant (two-sided p=0.125, per-protocol analysis; supported by the ITT and three sensitivity analyses). FDA judged the trial underpowered. missed
NCT01357642: Primary endpoint, AUC0-6h of percent change in FEV1 at week 12 (ITT): epinephrine HFA 250 mcg 40.59 (SD 56.09, n=248) vs placebo 12.76 (SD 55.77, n=61); mean difference 27.83 (95% CI 11.99 to 43.68), p<0.05. Epinephrine CFC active control: 35.67 (SD 45.70, n=64).
Salmeterol (DISKUS)ApprovedSmall moleculeBeta-2 adrenergic receptornot yet gradedNo reviewed efficacy summary in this indication
TerbutalineApprovedSmall moleculeBeta-2 adrenergic receptor (ADRB2)not yet gradedNo reviewed efficacy summary in this indication
Tezepelumab (Tezspire)ApprovedMonoclonal antibodyTSLP, Thymic stromal lymphopoietin (TSLP), ligand-neutralizingReliable signal
NCT03347279: Annual Asthma Exacerbation Rate in Adult and Adolescent Patients With Uncontrolled Asthma (From randomisation to Study Week 52.): Tezepelumab 210mg Q4W 0.93 events per year (95% CI 0.8 to 1.07) | Placebo 2.1 events per year (95% CI 1.84 to 2.39)
NCT03406078: Categorized Percent Reduction From Baseline in the Daily OCS Dose While Not Losing Asthma Control (Baseline to Week 48): Tezepelumab — >=90% to <=100% reduction: 40/74; >=75% to <90% reduction: 5/74; >=50% to <75% reduction: 10/74; >0% to <50% reduction: 5/74; no change or any increase: 14/74 vs Placebo — >=90% to <=100% reduction: 35/76; >=75% to <90% reduction: 4/76; >=50% to <75% reduction: 14/76; >0% to <50% reduction: 9/76; no change or any increase: 14/76 missed
Tiotropium BromideApprovedSmall moleculeMuscarinic acetylcholine receptor (M3)Reliable signal
NCT00772538: Peak Forced Expiratory Volume in 1 Second (FEV1) Response Within 3 Hours Post Dosing (0-3h) After a Treatment Period of 24 Weeks. (Baseline and 24 weeks): Tio R5 0.401 Liter (Standard Error 0.025) vs Placebo 0.315 Liter (Standard Error 0.026)
NCT00565266: Change Between Week 14 and Week 0 in the Morning (AM) Peak Expiratory Flow (PEF) (AM PEF was measured daily during each of the three 14-week treatment periods. The primary analysis constructed the change between week 14 and week 0.): Tio + 1xICS 24.4 Liters per minute (Standard Error 4.2) vs LABA + 1xICS 18 Liters per minute (Standard Error 3.2) vs 2xICS -1.4 Liters per minute (Standard Error 3.5)
Beclomethasone Dipropionate / Formoterol FumaratePhase 3Small moleculeGlucocorticoid receptor; β2-adrenergic receptorReliable signal
NCT05292586: 1_Change From Baseline in FEV1 AUC0-12h Normalised by Time at Week 12 (Baseline (pre-dose on Week 0) and Week 12.): CHF 1535 pMDI 0.279 liter (95% CI 0.248 to 0.309) vs CHF 718 pMDI 0.174 liter (95% CI 0.143 to 0.206)
FelcorekibartPhase 3Monoclonal antibodyTSLPnot yet gradedNo reviewed efficacy summary in this indication
FenoterolPhase 3Small moleculeBeta-2 adrenergic receptorPartial signalNo reviewed efficacy summary in this indication
Fenoterol / Ipratropium BromidePhase 3Small moleculeMuscarinic M3 receptor / Beta-2 adrenergic receptor (combination), Muscarinic acetylcholine receptor M3 and beta-2 adrenergic receptorReliable signal
NCT02182479: Primary, average FEV1 change from test-day baseline over 6 hours after dosing on day 85, non-inferiority of Respimat SMI (10/25 mcg and 20/50 mcg) vs pMDI (20/50 mcg): neither Respimat dose was inferior to the pMDI (p<0.001), met. Supportive: mean peak FEV1 increase on day 85 was 0.498 to 0.521 L with active treatment vs 0.215 and 0.240 L with placebo.
Indacaterol Maleate / Mometasone FuroatePhase 3—Glucocorticoid receptor / Beta-2 adrenergic receptorPartial signal
NCT02554786: Trough Forced Expiratory Volume in One Second (Trough FEV1) at Week 26 (26 weeks): QMF149 150/320 μg 2.383 litre (L) (Standard Error 0.0159) | QMF149 150/160 μg 2.387 litre (L) (Standard Error 0.016) | MF 800 μg 2.25 litre (L) (Standard Error 0.0162) | MF 400 μg 2.176 litre (L) (Standard Error 0.0162) | Salmeterol/Fluticasone 50/500 μg 2.346 litre (L) (Standard Error 0.016)
NCT02892344: Trough FEV1 (week 12): QMF149 150/80 μg 2.562 Liters (Standard Error 0.0134) | MF 200 µg 2.379 Liters (Standard Error 0.0134)
IpratropiumPhase 3Small moleculeMuscarinic acetylcholine receptor (M3)Weak signalNo reviewed efficacy summary in this indication
MasitinibPhase 3Small moleculeKIT (c-Kit), also PDGFR and Lyn/Fyn kinasesPartial signal
NCT01449162: Annualized severe asthma exacerbation rate (SAER), primary population, overall treatment exposure: masitinib reduced SAER by 35% vs placebo; rate ratio 0.65 (95% CI 0.47-0.90; P=0.010)
NCT03771040: Severe asthma exacerbations: 29% reduction vs placebo (p=0.022) in patients with eosinophils above 150/uL
OcankitugPhase 3Monoclonal antibodyTSLPnot yet gradedNo reviewed efficacy summary in this indication
Oxitropium Bromide (Ba253BINEB)Phase 3Small moleculeMuscarinic acetylcholine receptor (M3)Weak signalNo reviewed efficacy summary in this indication
RademikibartPhase 3Monoclonal antibodyIL-4R-alphanot yet gradedNo reviewed efficacy summary in this indication
Salbutamol HFA-152aPhase 3Small moleculeBeta-2 adrenergic receptorWeak signal
NCT06261957: Primary outcomes, safety (no formal efficacy test): participants with an adverse event in the treatment period 108/338 (HFA-152a) vs 36/112 (HFA-134a); none in the run-in period (0/471); serious adverse events 6/338 vs 3/112 (CT.gov posted results).
TilrekimigPhase 3Multispecific antibodyIL-4/IL-13/TSLPnot yet gradedNo reviewed efficacy summary in this indication
VilanterolPhase 3Small moleculeBeta-2 adrenergic receptorPartial signal
NCT00600171: Mean Change From Baseline in Clinic Visit Trough FEV1 at Day 28 (Last Observation Carried Forward [LOCF]) (Baseline and Day 28): GW642444M 3 µg 0.212 Liters (Standard Error 0.036) | GW642444M 6.25 µg 0.217 Liters (Standard Error 0.035) | GW642444M 12.5 µg 0.278 Liters (Standard Error 0.036) | GW642444M 25 µg 0.269 Liters (Standard Error 0.035) | GW642444M 50 µg 0.309 Liters (Standard Error 0.035) vs Placebo 0.147 Liters (Standard Error 0.036)
Glycopyrronium (PT001)Phase 2/3Small moleculeMuscarinic acetylcholine receptor (M3)Partial signal
NCT03358147: Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) Area Under the Curve From 0 to 4 Hours (AUC0-4) (Week 24): GP MDI 28.8 μg 0.294 Liter (95% CI 0.248 to 0.341) | GP MDI 14.4 μg 0.284 Liter (95% CI 0.238 to 0.331) | GP MDI 7.2 μg 0.308 Liter (95% CI 0.263 to 0.354) vs Placebo MDI 0.24 Liter (95% CI 0.194 to 0.287) | Spiriva Respimat 2.5 μg 0.347 Liter (95% CI 0.282 to 0.412)
StapokibartPhase 2/3Monoclonal antibodyIL-4R-alphanot yet gradedNo reviewed efficacy summary in this indication
WIN378Phase 2/3Monoclonal antibodyTSLPWeak signalFeatured results are safety only in this race
AK139Phase 2Multispecific antibodyIL-4 receptor alpha / ST2not yet gradedNo reviewed efficacy summary in this indication
ARO-RAGEPhase 2RNA / oligonucleotideRAGE (receptor for advanced glycation end-products)Weak signalFeatured results are safety only in this race
BrenipatidePhase 2PeptideGLP-1/GIP receptor (dual)not yet gradedNo reviewed efficacy summary in this indication
CM512Phase 2Multispecific antibodyTSLP + IL-13not yet gradedNo reviewed efficacy summary in this indication
ENV-294Phase 2Small molecule—not yet gradedNo reviewed efficacy summary in this indication
Freneslerbart / MevonlerbartPhase 2Monoclonal antibodyFel d 1 (major cat allergen protein)Reliable signal
NCT03838731: Primary endpoint, time to early asthmatic reaction at Week 1 following single dose: >4 hours (REGN1908-1909) vs 51 minutes (placebo), p=0.0083
FrevecitinibPhase 2Small moleculeJAK1/2/3/TYK2Weak signalNo reviewed efficacy summary in this indication
KT-621Phase 2Small moleculeSTAT6not yet gradedNo reviewed efficacy summary in this indication
LunsekimigPhase 2Antibody-derived scaffoldTSLP + IL-13Weak signalFeatured results are safety only in this race
OpSCF
Phase 2(overall)
Monoclonal antibodyStem cell factor (SCF / KIT ligand)not yet gradedNo reviewed efficacy summary in this indication
PBF-680Phase 2—Adenosine A1 receptorPartial signal
NCT03774290: Trough FEV1 change from baseline at Day 16: placebo 2.88±0.10 L vs PBF-680 3.06±0.09 L; +180 mL mean increase over placebo (P=0.0816, pre-specified alpha=0.1)
QuisovalimabPhase 2Monoclonal antibodyLIGHT (TNFSF14)Partial signal
NCT05288504: Participants with an asthma-related event through week 14: AVTX-002 12 vs placebo 14 (CT.gov posted counts); the sponsor states the primary endpoint was not met. missed
RC1416Phase 2Multispecific antibodyIL-4 / IL-5 / IL-13not yet gradedNo reviewed efficacy summary in this indication
RilzabrutinibPhase 2Small moleculeBTKPartial signal
NCT05104892: Primary endpoint (LOAC events at Week 12): high-dose rilzabrutinib 36% relative risk reduction vs placebo (OR 0.584, 95% CI 0.253-1.349); low-dose 25% relative risk reduction (OR 0.570, 95% CI 0.202-1.608). missed
SunakimentPhase 2Antibody fragmentTSLPPartial signalFeatured results are safety only in this race
TozorakimabPhase 2Monoclonal antibodyIL-33Partial signal
NCT04570657: Change from baseline to week 16 in clinic pre-bronchodilator FEV1 vs placebo (LSMD, 80% CI): tozorakimab 600 mg +4 mL (-71 to 79), p=0.473; tozorakimab 300 mg +36 mL (-38 to 111), p=0.267 missed
Umeclidinium (Incruse Ellipta)Phase 2Small moleculeMuscarinic acetylcholine receptor (M3)Partial signal
NCT01573624: Model Predicted Change From Baseline Trough Force Expiratory Volume in 1 Second (FEV1) (Baseline (Day 1) and Day 15 of each treatment period): FF 100 mcg + UMEC 15.6 mcg 0.026 Litres (L) (95% CI -0.0098 to 0.0611) | FF 100 mcg + UMEC 31.25 mcg 0.032 Litres (L) (95% CI -0.0036 to 0.0679) | FF 100 mcg + UMEC 62.5 mcg 0.0385 Litres (L) (95% CI -0.0011 to 0.0745) | FF 100 mcg + UMEC 125 mcg 0.0444 Litres (L) (95% CI 0.0067 to 0.0813) | FF 100 mcg + UMEC 250 mcg 0.051 Litres (L) (95% CI 0.0139 to 0.0873)
NCT01641692: Final Dose-response Model for Trough Forced Expiratory Volume in One Second (FEV1) (Day 15 of each treatment period (up to Study Day 71)): All Study Treatments — Theta1 (mean Baseline): 0.0363 unitless (95% CI 0.028 to 0.045); Theta2 (period Baseline): -0.97 unitless (95% CI -1.06 to -0.881); Omega (mean Baseline): 0.00371 unitless (95% CI 0.002 to 0.005); Omega (period Baseline): 0.149 unitless (95% CI 0 to 0.298); Sigma (Variance of Residual error): 0.0393 unitless (95% CI 0.028 to 0.05)
VerekitugPhase 2Monoclonal antibodyTSLP receptorReliable signal
NCT06196879: Annualized Asthma Exacerbation Rate (AAER) reduction vs placebo (VALIANT): -56% at verekitug 100 mg q12w (p<0.0003); -39% at 400 mg q24w (p<0.02)
BriquilimabPhase 1Monoclonal antibodyKITPartial signalFeatured results are safety only in this race
ItepekimabDiscontinuedMonoclonal antibodyIL-33not yet gradedNo reviewed efficacy summary in this indication

Large race: only the 68 furthest-along competitors are listed; 19 more exist in this indication but aren't shown. Use the search box to compare against any of them.

Upcoming events

(35 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Dupixent (dupilumab) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (4)
November 2026 (1)
Phase 3Atopic DermatitisActive not recruiting
Est. primary completion 2026-11 · NCT06389136 · CT.gov ↗
What to watch
December 2026 (3)
Phase 1/2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2026-12-01 · NCT06088771 · CT.gov ↗
What to watch
Phase 2Hypereosinophilic SyndromeRecruiting
Est. primary completion 2026-12-30 · NCT06477653 · CT.gov ↗
What to watch
Phase 2AsthmaActive not recruiting
Est. primary completion 2026-12-31 · NCT05347771 · CT.gov ↗
What to watch
2027 (18)
January 2027 (2)
Phase 4AsthmaActive not recruiting
Est. primary completion 2027-01 · NCT03694158 · CT.gov ↗
What to watch
Phase 2/3Skin Inflammation, Allergic Contact DermatitisActive not recruiting
Est. primary completion 2027-01-01 · NCT05535738 · CT.gov ↗
What to watch
February 2027 (1)
Phase 4Atopic DermatitisNot yet recruiting
Est. primary completion 2027-02-07 · NCT07905547 · CT.gov ↗
What to watch
March 2027 (2)
Phase 1Locally Advanced Triple Negative Breast Cancer, TNBC - Triple-Negative Breast CancerRecruiting
Est. primary completion 2027-03-10 · NCT06637306 · CT.gov ↗
What to watch
Phase 4AsthmaActive not recruiting
Est. primary completion 2027-03-16 · NCT05097287 · CT.gov ↗
What to watch
April 2027 (2)
Phase 4AsthmaActive not recruiting
Est. primary completion 2027-04-24 · NCT06572228 · CT.gov ↗
What to watch
Phase 4Atopic DermatitisActive not recruiting
Est. primary completion 2027-04-29 · NCT05983068 · CT.gov ↗
What to watch
June 2027 (3)
Phase 4Atopic DermatitisRecruiting
Est. primary completion 2027-06 · NCT05042258 · CT.gov ↗
What to watch
Phase 3PruritusRecruiting
Est. primary completion 2027-06-02 · NCT05263206 · CT.gov ↗
What to watch
Phase 4AsthmaRecruiting
Est. primary completion 2027-06-30 · NCT06385236 · CT.gov ↗
What to watch
July 2027 (1)
Phase 4Atopic DermatitisRecruiting
Est. primary completion 2027-07 · NCT05268107 · CT.gov ↗
What to watch
October 2027 (1)
Phase 3Prurigo NodularisRecruiting
Est. primary completion 2027-10-28 · NCT06293053 · CT.gov ↗
What to watch
November 2027 (1)
Phase 2Alopecia AreataRecruiting
Est. primary completion 2027-11-30 · NCT05551793 · CT.gov ↗
What to watch
December 2027 (5)
Phase 1Eosinophilic EsophagitisEnrolling by invitation
Est. primary completion 2027-12 · NCT07358234 · CT.gov ↗
What to watch
Phase 4AsthmaRecruiting
Est. primary completion 2027-12 · NCT04743791 · CT.gov ↗
What to watch
Early phase / not applicableNon-Small Cell Lung Cancer, Immunotherapy, Neoadjuvant TherapyRecruiting
Est. primary completion 2027-12 · NCT06743581 · CT.gov ↗
What to watch
Phase 2PruritisRecruiting
Est. primary completion 2027-12-31 · NCT06226610 · CT.gov ↗
What to watch
Phase 4AsthmaRecruiting
Est. primary completion 2027-12-31 · NCT06818019 · CT.gov ↗
What to watch
2028 (9)
February 2028 (2)
Phase 4Atopic DermatitisRecruiting
Est. primary completion 2028-02-01 · NCT05858619 · CT.gov ↗
What to watch
Phase 2Nephrotic Syndrome in Children, Nephrotic Syndrome Steroid-DependentRecruiting
Est. primary completion 2028-02-28 · NCT07091175 · CT.gov ↗
What to watch
May 2028 (1)
Phase 3Atopic DermatitisNot yet recruiting
Est. primary completion 2028-05-02 · NCT07919899 · CT.gov ↗
What to watch
June 2028 (1)
Phase 3Eosinophilic EsophagitisRecruiting
Est. primary completion 2028-06-19 · NCT07112378 · CT.gov ↗
What to watch
July 2028 (1)
Phase 4Chronic Obstructive Pulmonary DiseaseRecruiting
Est. primary completion 2028-07-30 · NCT07587658 · CT.gov ↗
What to watch
December 2028 (4)
Phase 2Major Depressive DisorderRecruiting
Est. primary completion 2028-12 · NCT07908563 · CT.gov ↗
What to watch
Phase 3AsthmaEnrolling by invitation
Est. primary completion 2028-12-21 · NCT06191315 · CT.gov ↗
What to watch
Phase 4Chronic Obstructive Pulmonary DiseaseRecruiting
Est. primary completion 2028-12-23 · NCT07053423 · CT.gov ↗
What to watch
Phase 1/2Metastatic Colorectal Cancer, Liver MetastasesRecruiting
Est. primary completion 2028-12-31 · NCT07277322 · CT.gov ↗
What to watch
2029 (2)
January 2029 (1)
Phase 3AsthmaRecruiting
Est. primary completion 2029-01 · NCT07309614 · CT.gov ↗
What to watch
March 2029 (1)
Phase 2Alopecia AreataRecruiting
Est. primary completion 2029-03-31 · NCT05866562 · CT.gov ↗
What to watch
2031 (1)
June 2031 (1)
Phase 1Skin DiseasesRecruiting
Est. primary completion 2031-06-30 · NCT05649098 · CT.gov ↗
What to watch
2034 (1)
September 2034 (1)
Early phase / not applicableRhinosinusitis Chronic, Nasal PolypsRecruiting
Est. primary completion 2034-09-02 · NCT06501807 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(9)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

22 April 2026ApprovalFDA approves Dupixent for CSU in children aged 2 to 11
US, FDA · Source ↗
13 April 2026ApprovalDupixent approved in the EU for CSU in children aged 2 to 11
EU, EMA · Source ↗
April 2026FDA action dateFDA decision expected by April 2026 for CSU in children
US, FDA · Source ↗
24 March 2026ApprovalDupixent approved in Japan for bullous pemphigoid
JP, MHLW · Source ↗
27 February 2026Filing acceptedFDA accepts sBLA for Dupixent in children 2-11 with CSU
US, FDA · Source ↗
24 February 2026ApprovalFDA approves Dupixent for allergic fungal rhinosinusitis
US, FDA · Source ↗
18 April 2025ApprovalDupixent approved in the US for chronic spontaneous urticaria
US, FDA · Source ↗
18 February 2025Filing acceptedDupixent sBLA accepted by FDA for bullous pemphigoid
US, FDA · Source ↗
18 February 2025Priority reviewFDA priority review for Dupixent in bullous pemphigoid
US, FDA · Source ↗